Price Chart

Profile

Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
URL https://www.altimmune.com
Investor Relations URL https://ir.altimmune.com/
HQ State/Province Maryland
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 28, 2024 (est.)
Last Earnings Release Nov. 07, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Jan. 20, 2017

Profile

Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
URL https://www.altimmune.com
Investor Relations URL https://ir.altimmune.com/
HQ State/Province Maryland
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 28, 2024 (est.)
Last Earnings Release Nov. 07, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Jan. 20, 2017